NCT04551586View on ClinicalTrials.gov

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

October 19, 2020

Study Completion Date

October 19, 2020

Conditions
Healthy
Interventions
DRUG

ACH-0145228: Immediate Release

ACH-0145228 (240 milligrams) will be administered orally on Day 1.

DRUG

ACH-0145228: Powder-in-capsule

ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Trial Locations (1)

68502

Clinical Trial Site, Lincoln

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY

NCT04551586 - A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants | Biotech Hunter | Biotech Hunter